SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) August 17, 1999
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc., subsidiary, IDT, Inc.,
announced today that it has filed its Preliminary Prospectus
on Form S-1 with the U.S. Securities and Exchange Commission
in connection with its Initial Public Offering. The filing is
available via EDGAR at the SEC's website: www.sec.gov.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information and Exhibits.
(a) Financial Statements and Businesses Acquired - Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: August 17, 1999
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.429.0673 phone
1.412.279.9690 fax 1.412.279.5041 fax
BIOCONTROL'S DIASENSOR DISPLAYED AT AMERICAN DIABETES ASSOCIATION
ANNUAL BIOCONTROL SUBSIDIARY, IDT, FILES IPO
Pittsburgh, PA - August 17, 1999 - Biocontrol Technology,
Inc. (OTCBB:BICO) subsidiary, IDT, Inc., announced today that it
has filed its Preliminary Prospectus on Form S-1 with the U.S.
Securities and Exchange Commission in connection with its Initial
Public Offering. The filing is available via EDGAR at the SEC's
website: www.sec.gov.
IDT's focus is on the development of the ThermoChem
technology and related disposables to deliver regional and whole
body hyperthermia in conjunction with surgery, chemotherapy and
radiation as a safe treatment for certain types of cancer and to
be used in conjunction with the current drug regimes in the
treatment of HIV.
Biocontrol Technology has its corporate offices in
Pittsburgh, PA and is involved in the development and manufacture
of biomedical devices and environmental products. IDT, Inc., a
wholly-owned subsidiary of Biocontrol also located in Pittsburgh,
PA, holds exclusive worldwide marketing rights to the ThermoChem-
HT SystemT and related disposables.
This document is neither an offer to sell nor a solicitation of
any offer to buy any securities, nor does it involve the
distribution of any securities; such offers or distributions may
only be made by the prospectus after regulatory requirements are
met.
WEBSITE: www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER: 1.800.357.6204